Bone metastases from renal cell carcinoma: 4 years after aggressive surgeries and anti-angiogenic therapy.

Autor: Nefiss M; Department of Orthopaedic Surgery Mongi Slim University Hospital La Marsa Tunisia.; Tunis El Manar University Tunis Tunisia., Abid H; Department of Orthopaedic Surgery Mongi Slim University Hospital La Marsa Tunisia.; Tunis El Manar University Tunis Tunisia., Gharbi MA; Department of Orthopaedic Surgery Mongi Slim University Hospital La Marsa Tunisia.; Tunis El Manar University Tunis Tunisia., Bouzidi R; Department of Orthopaedic Surgery Mongi Slim University Hospital La Marsa Tunisia.; Tunis El Manar University Tunis Tunisia., Teborbi A; Department of Orthopaedic Surgery Mongi Slim University Hospital La Marsa Tunisia.; Tunis El Manar University Tunis Tunisia.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2022 Nov 15; Vol. 10 (11), pp. e6599. Date of Electronic Publication: 2022 Nov 15 (Print Publication: 2022).
DOI: 10.1002/ccr3.6599
Abstrakt: Management of bone metastases from renal cell carcinoma (RCC) has significantly changed after the era of targeted therapy that improved the overall survival (OS). Surgical decision-making remains a subject of controversy. We report a case of pelvic bone metastasis from RCC, 2 months after nephrectomy and surgery of a revealing clavicular metastasis.
Competing Interests: The authors have no conflicts of interest to declare.
(© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje